


Leukemia & Lymphoma >
Volume 56, 2015 - Issue 4232 | 3 | 0
Views CrossRef citations to date Altmetric

Original Article: Clinical

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma

Eric Jacobsen , Olga Pozdnyakova, Robert Redd, David C. Fisher, David M. Dorfman, Paola Dal Cin, ... show all

Pages 993-998 | Received 03 Jun 2014, Accepted 30 Jun 2014, Published online: 20 Aug 2014

 Cite this article  <https://doi.org/10.3109/10428194.2014.941835>

Sample our
Medicine, Dentistry, Nursing
& Allied Health Journals
>> **Sign in here** to start your access
to the latest two volumes for 14 days

 Full Article  Figures & data  References  Supplemental  Citations  Metrics

 Reprints & Permissions [Read this article](#)

Abstract

Platelet derived growth factor- α (PDGFR- α) is expressed in peripheral T cell lymphoma, not otherwise specified (PTCL, NOS). Imatinib mesylate demonstrated in vitro cytotoxicity against primary PTCL, NOS cells. We initiated a trial of imatinib in 12

patients with relapsed/refractory peripheral T cell lymphoma (PTCL, NOS). PDGFR- α expressing cells were identified by fluorescence in situ hybridization (FISH) to assess for imatinib response. The study enrolled 12 patients with relapsed/refractory PTCL, NOS. The overall survival of PDGFR- α expressing cells was 100%. The overall survival of PDGFR- α expressing cells was 100%. The overall survival of PDGFR- α expressing cells was 100%.

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click "Settings". For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings

an unselected group of patients in which PDGFR- α expression was not required for study entry.

Keywords:: Lymphoma imatinib PDGFR- α

[Previous article](#)

[View issue table of contents](#)

[Next article](#)

Potential conflict of interest:

[Disclosure](#) forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Related research

People also read

Recommended articles

Cited by
3

Targeting neddylation effectively antagonizes nuclear factor- κ B in chronic lymphocytic leukemia B-cells [➤](#)


J. Claire Godbersen et al.
Leukemia & Lymphoma
Published online: 29 May 2015

A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia [➤](#)

Paolo Strati et al.
Leukemia & Lymphoma
Published online: 29 May 2015

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

 Accept All

Essential Only

Settings



Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

Keep up to date

Register to receive personalised research and resources by email



Sign me up



Copyright © 2024 Informa UK Limited [Privacy policy](#) [Cookies](#) [Terms & conditions](#)

[Accessibility](#)



Taylor & Francis Group
an informa business

Registered in England & Wales No. 3099067
5 Howick Place | London | SW1P 1WG

About Cookies On This Site

We and our partners use cookies to enhance your website experience, learn how our site is used, offer personalised features, measure the effectiveness of our services, and tailor content and ads to your interests while you navigate on the web or interact with us across devices. You can choose to accept all of these cookies or only essential cookies. To learn more or manage your preferences, click “Settings”. For further information about the data we collect from you, please see our [Privacy Policy](#).

Accept All

Essential Only

Settings